Head and Neck Carcinoma, Other — Trials

Head and Neck Carcinoma, Other — Trials · CancerIndex

Clinical trials

Registered studies

128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 35
Recruiting: 17
Ph III recruiting: 1
Growth YoY: —
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04116359	Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma	withdrawn	Phase 1 / Phase 2	0	National Cancer Institute (NCI)NIH	0	Sep 28, 2020	clinicaltrials
NCT02831179	Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor	withdrawn	Phase 1	0	Vanderbilt-Ingram Cancer CenterOTHER	0	Sep 28, 2017